Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy-Reference-Cited by-同舟云学术

Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy

Published:2017-11 Issue:11 Volume:28 Page:2707-2714
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

McCoach C.E.^ORCID,Blumenthal G.M.,Zhang L.,Myers A.,Tang S.,Sridhara R.,Keegan P.,Pazdur R.,Doebele R.C.,Kazandjian D.

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/11/2707/25731295/mdx414.pdf

Reference20 articles.

1. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009

2. Crizotinib in ROS1-rearranged non-small-cell lung cancer;Shaw;N Engl J Med,2014

3. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

5. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune‐inflammatory markers and clinical characteristics as predictors of the depth of response and prognosis of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer receiving first‐line immunotherapy;Thoracic Cancer;2024-08-27

2. Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort;Investigational New Drugs;2024-08-21

3. Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations;Neoplasia;2024-07

4. A bootstrapping method to optimize go/no‐go decisions from single‐arm, signal‐finding studies in oncology;CPT: Pharmacometrics & Systems Pharmacology;2024-06-11

5. Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials;Nature Reviews Clinical Oncology;2024-04-10